Technology

Introducing StimOxyGen’s groundbreaking lead solution, SGEN-33, designed to revolutionize cancer treatment. SGEN-33 represents a pioneering approach in addressing tumor hypoxia, a critical barrier to effective radiotherapy across various solid tumors.

SGEN-33 is engineered to tackle the challenge of hypoxia by generating transient oxygen directly within the tumor microenvironment. By leveraging nanoparticle technology, SGEN-33 transiently increases the oxygen supply within tumors, enhancing the efficacy of radiotherapy. This innovative approach not only amplifies the radiation dose absorbed by tumor cells but also minimizes exposure to healthy tissues, optimizing treatment outcomes.

With its potential as a first-in-class radioenhancer, SGEN-33 offers promising therapeutic applications across a spectrum of solid tumors. By precisely targeting tumor hypoxia, SGEN-33 not only enhances treatment of primary tumors but also primes the immune system to combat metastatic tumors, paving the way for a comprehensive and effective cancer treatment strategy.

Join us in redefining the landscape of cancer therapy with StimOxyGen – a groundbreaking solution poised to transform the standard of care for cancer patients worldwide.